Genflow Biosciences plc

Genflow Biosciences plc is a biotechnology firm dedicated to devising biological treatments aimed at confronting the impacts of aging. Their goal is to slow down or completely stop the aging process and reduce the frequency of age-related illnesses, thereby extending the period of good health (healthspan). Their primary therapeutic asset is GF-1002, an adeno-associated viral vector-based gene therapy delivered through intravenous infusion. The company's pipeline also features GF-3001, a topical application of SIRT6 for skin treatment, and GF-4001, an anti-aging solution developed for veterinary use in non-human animals. Established in 2021, Genflow Biosciences plc is headquartered in London, United Kingdom.